bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S2 from Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients
Authors: Chen Yuan , Xue Shao-An , Behboudi Shahriar , Mohammad Goran H. , Pereira Stephen P. , Morris Emma C.
Published: April 2023

Figure S2 shows CEA691-specific cytotoxic activity of CTL lines isolated from PC patients. A. T cell line from CA11 were measured for their capability to recognise and kill T2 cells coated with 1mM (10-6 M) of CEA691, compared to control peptide, in 4-h CFSE cytotoxicity assay . B. The percentage specific cytotoxicity of CEA 691 loaded T2 cells (1mM peptide) at various E:T ratio, using CTL lines from 3 PC patients (CA07, 11, and 18). C. The cytotoxicity of T cells from CA11 against T2 cells coated with 10-5 to 10-12 M CEA691 peptide and control peptide, at E:T ratio 20:1 (left). The cytotoxicity curve was summarised on the bottom (D).
Table S1 from Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Authors: Bayraktar Recep , Ivan Cristina , Bayraktar Emine , Kanlikilicer Pinar , Kabil Nashwa N. , Kahraman Nermin , Mokhlis Hamada A. , Karakas Didem , Rodriguez-Aguayo Cristian , Arslan Ahmet , Sheng Jianting , Wong Stephen , Lopez-Berestein Gabriel , Calin George A. , Ozpolat Bulent
Published: April 2023

Interaction between molecular subtype and eEF2K and FOXM1 expression on overall survival in breast cancer patients.
Figure S1 from Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Authors: Bayraktar Recep , Ivan Cristina , Bayraktar Emine , Kanlikilicer Pinar , Kabil Nashwa N. , Kahraman Nermin , Mokhlis Hamada A. , Karakas Didem , Rodriguez-Aguayo Cristian , Arslan Ahmet , Sheng Jianting , Wong Stephen , Lopez-Berestein Gabriel , Calin George A. , Ozpolat Bulent
Published: April 2023

Ectopic expression of miR-34a increases relative miR-34a expression levels in MDA-MB-231 and MDA-MB-436 cells.
Table S2 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Table S2. NOTCH4 and HEY1 high/low group clinical demographics in TCGA
Supplementary Methods from Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
Authors: Hui Edwin P. , Ma Brigette B. Y. , Loong Herbert H. F. , Mo Frankie , Li Leung , King Ann D. , Wang Ki , Ahuja Anil T. , Chan Charles M. L. , Hui Connie W. C. , Wong Chi H. , Chan Anthony T. C.
Published: April 2023

Supplementary Methods
Supplemental Materials from A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
Authors: Pardee Timothy S. , Anderson Rebecca G. , Pladna Kristin M. , Isom Scott , Ghiraldeli Lais P. , Miller Lance D. , Chou Jeff W. , Jin Guangxu , Zhang Wei , Ellis Leslie R. , Berenzon Dmitriy , Howard Dianna S. , Hurd David D. , Manuel Megan , Dralle Sarah , Lyerly Susan , Powell Bayard L.
Published: April 2023

Figure S1. Dose escalation schema. Figure S2. Acetyl-CoA synthetase is expressed in OCI-AML3 and MFL2 cells. Figure S3 Acetate and methyl-succinate rescue of CPI-613 cytotoxicity. Figure S4. Treatment schema. Figure S5. Efficacy of HiDAC, mitoxantrone and CPI-613. Figure S6. Baseline bone marrow mononuclear cell gene expression profiles of responders (n=10) versus nonresponders (n=7). Figure S7. SOD2 expression levels are higher in non-responders Figure S8. SOD2 confers resistance to CPI-613. Figure S9. Mutational analysis from RNA sequence data of baseline marrow samples. Supplemental Table 1. Dose and Response by Patient Supplementary Table 2. Gene ontology enrichment analysis of genes overexpressed in responding patients
Supplementary information from Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis
Authors: Yamamoto Takamasa , Kawada Kenji , Itatani Yoshiro , Inamoto Susumu , Okamura Ryosuke , Iwamoto Masayoshi , Miyamoto Ei , Chen-Yoshikawa Toyofumi F. , Hirai Hideyo , Hasegawa Suguru , Date Hiroshi , Taketo Makoto M. , Sakai Yoshiharu
Published: April 2023

Supplementary information contains figure legends of all supplementary figures (1-6).
Supplementary Figure 5 from Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis
Authors: Yamamoto Takamasa , Kawada Kenji , Itatani Yoshiro , Inamoto Susumu , Okamura Ryosuke , Iwamoto Masayoshi , Miyamoto Ei , Chen-Yoshikawa Toyofumi F. , Hirai Hideyo , Hasegawa Suguru , Date Hiroshi , Taketo Makoto M. , Sakai Yoshiharu
Published: April 2023

Simultaneous immunofluorescence staining for CCR1 (red) and CD11b (A), CD33 (B), HLA-DR (C), or CD15 (D) (green).
Supplementary Figure 4 from Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis
Authors: Yamamoto Takamasa , Kawada Kenji , Itatani Yoshiro , Inamoto Susumu , Okamura Ryosuke , Iwamoto Masayoshi , Miyamoto Ei , Chen-Yoshikawa Toyofumi F. , Hirai Hideyo , Hasegawa Suguru , Date Hiroshi , Taketo Makoto M. , Sakai Yoshiharu
Published: April 2023

Simultaneous immunofluorescence staining for CCR1 (red) and CD3 (A), CD8 (B), CD68 (C), α-SMA (D), CD14 (E), or CXCR2 (F) (green).
Movie S3 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Authors: Zhang Gao , Wu Lawrence W. , Mender Ilgen , Barzily-Rokni Michal , Hammond Marc R. , Ope Omotayo , Cheng Chaoran , Vasilopoulos Themistoklis , Randell Sergio , Sadek Norah , Beroard Aurelie , Xiao Min , Tian Tian , Tan Jiufeng , Saeed Umar , Sugarman Eric , Krepler Clemens , Brafford Patricia , Sproesser Katrin , Murugan Sengottuvelan , Somasundaram Rajasekharan , Garman Bradley , Wubbenhorst Bradley , Woo Jonathan , Yin Xiangfan , Liu Qin , Frederick Dennie T. , Miao Benchun , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Kwong Lawrence N. , Amaravadi Ravi K. , Lu Yiling , Boland Genevieve M. , Wei Zhi , Nathanson Katherine , Herbig Utz , Mills Gordon B. , Flaherty Keith T. , Herlyn Meenhard , Shay Jerry W.
Published: April 2023

Time-lapse imaging of A375(Fucci2)-BR cells treated with the control.
Movie S2 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Authors: Zhang Gao , Wu Lawrence W. , Mender Ilgen , Barzily-Rokni Michal , Hammond Marc R. , Ope Omotayo , Cheng Chaoran , Vasilopoulos Themistoklis , Randell Sergio , Sadek Norah , Beroard Aurelie , Xiao Min , Tian Tian , Tan Jiufeng , Saeed Umar , Sugarman Eric , Krepler Clemens , Brafford Patricia , Sproesser Katrin , Murugan Sengottuvelan , Somasundaram Rajasekharan , Garman Bradley , Wubbenhorst Bradley , Woo Jonathan , Yin Xiangfan , Liu Qin , Frederick Dennie T. , Miao Benchun , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Kwong Lawrence N. , Amaravadi Ravi K. , Lu Yiling , Boland Genevieve M. , Wei Zhi , Nathanson Katherine , Herbig Utz , Mills Gordon B. , Flaherty Keith T. , Herlyn Meenhard , Shay Jerry W.
Published: April 2023

Time-lapse imaging of A375(Fucci2) cells treated with 6-thio-dG.
Supplemental Figure 3 from Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Authors: Loree Jonathan M. , Pereira Allan A.L. , Lam Michael , Willauer Alexandra N. , Raghav Kanwal , Dasari Arvind , Morris Van. K , Advani Shailesh , Menter David G. , Eng Cathy , Shaw Kenna , Broaddus Russell , Routbort Mark J. , Liu Yusha , Morris Jeffrey S. , Luthra Rajyalakshmi , Meric-Bernstam Funda , Overman Michael J. , Maru Dipen , Kopetz Scott
Published: April 2023

Comparison of overall survival based on primary tumor side using a multivariate proportional hazards model controlling for co-variates that differed based on tumor location.
Supplementary Table 3 from Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma
Authors: Chicard Mathieu , Colmet-Daage Leo , Clement Nathalie , Danzon Adrien , Bohec Mylène , Bernard Virginie , Baulande Sylvain , Bellini Angela , Deveau Paul , Pierron Gaëlle , Lapouble Eve , Janoueix-Lerosey Isabelle , Peuchmaur Michel , Corradini Nadège , Defachelles Anne Sophie , Valteau-Couanet Dominique , Michon Jean , Combaret Valérie , Delattre Olivier , Schleiermacher Gudrun
Published: April 2023

Table S3: SNVs detected in primary solid Tumor at diagnosis (n=19), Relapse Tumor (n=4 previously published cases), cfDNA at diagnosis (n=19) and cfDNA with relapse (n=9) with WES.
Supplementary Table 1 from Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study
Authors: Nieuweboer Annemieke J.M. , de Graan Anne-Joy M. , Hamberg Paul , Bins Sander , van Soest Robert J. , van Alphen Robbert J. , Bergman Andries M. , Beeker Aart , van Halteren Henk , ten Tije Albert J. , Zuetenhorst Hanneke , van der Meer Nelly , Chitu Dana , de Wit Ronald , Mathijssen Ron H.J.
Published: April 2023

Patient inclusion per participating medical center
Table S1 from PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity
Authors: Buchan Sarah L. , Fallatah Mohannad , Thirdborough Stephen M. , Taraban Vadim Y. , Rogel Anne , Thomas Lawrence J. , Penfold Christine A. , He Li-Zhen , Curran Michael A. , Keler Tibor , Al-Shamkhani Aymen
Published: April 2023

List of genes represented in the heatmap
Table S2-4 from Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer
Authors: Chen Xin , Chen Zhenyao , Yu Shanxun , Nie Fengqi , Yan Shuai , Ma Pei , Chen Qinnan , Wei Chenchen , Fu Hangjiang , Xu Tianwei , Ren Shengnan , Sun Ming , Wang Zhaoxia
Published: April 2023

Correlation between LINC01234,other factors and GC patients prognosis
Figures S1-S5 from PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity
Authors: Buchan Sarah L. , Fallatah Mohannad , Thirdborough Stephen M. , Taraban Vadim Y. , Rogel Anne , Thomas Lawrence J. , Penfold Christine A. , He Li-Zhen , Curran Michael A. , Keler Tibor , Al-Shamkhani Aymen
Published: April 2023

Figure S1: Agonist anti-CD27 is superior to other anti-TNFRSF mAbs for CD8+ T-cell expansion in vivo; Figure S2: Agonist anti-CD27 and PD-1/L1 blockade combine to promote expansion of OT-I T cells in response to high and low affinity peptides; Figure S3: Purity of pmel1 CD8+ T cells prior to microarray analysis; Figure S4: Agonist anti-CD27 and PD-1 blockade synergize for improved adoptive T-cell therapy; Figure S5: Agonist anti-CD27 and anti-PD-L1 synergize to impair tumor growth and improve local CD8+ T-cell accumulation in a vaccination model.
Figure S4 from Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer
Authors: Chen Xin , Chen Zhenyao , Yu Shanxun , Nie Fengqi , Yan Shuai , Ma Pei , Chen Qinnan , Wei Chenchen , Fu Hangjiang , Xu Tianwei , Ren Shengnan , Sun Ming , Wang Zhaoxia
Published: April 2023

The effect of CBFB on GC cells proliferation in vitro,and tumor growth in vivo
Supplementary Figure S3 from Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases
Authors: Chan Nancy , Willis Amy , Kornhauser Naomi , Ward Maureen M. , Lee Sharrell B. , Nackos Eleni , Seo Bo Ri , Chuang Ellen , Cigler Tessa , Moore Anne , Donovan Diana , Vallee Cobham Marta , Fitzpatrick Veronica , Schneider Sarah , Wiener Alysia , Guillaume-Abraham Jessica , Aljom Elnaz , Zelkowitz Richard , Warren J. David , Lane Maureen E. , Fischbach Claudia , Mittal Vivek , Vahdat Linda
Published: April 2023

The top panel shows the reaction chemistry of established lysyl oxidase (LOX) activity assay. The bottom panel shows the Amplex Red/HRP-based LOX activity assay that detects LOX activity in vitro.
Suppl. Figure 3 from Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Authors: Theodoraki Marie-Nicole , Yerneni Saigopalakrishna S. , Hoffmann Thomas K. , Gooding William E. , Whiteside Theresa L.
Published: April 2023

RFVs for PD-L1+ or PD-1+ exosomes
Supplementary Figures from Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Authors: Chen Ying , Camacho Sandra Catalina , Silvers Thomas R. , Razak Albiruni R.A. , Gabrail Nashat Y. , Gerecitano John F. , Kalir Eva , Pereira Elena , Evans Brad R. , Ramus Susan J. , Huang Fei , Priedigkeit Nolan , Rodriguez Estefania , Donovan Michael , Khan Faisal , Kalir Tamara , Sebra Robert , Uzilov Andrew , Chen Rong , Sinha Rileen , Halpert Richard , Billaud Jean-Noel , Shacham Sharon , McCauley Dilara , Landesman Yosef , Rashal Tami , Kauffman Michael , Mirza Mansoor R. , Mau-Sørensen Morten , Dottino Peter , Martignetti John A.
Published: April 2023

Supplementary Figure 1. Overview of XPO1's role in nuclear:cytoplasmic transport. Supplementary Figure 2. KPT-185 is much less toxic to patient-derived benign cells than patient-derived serous high grade OvCa cells. Supplementary Figure 3. FACS cell cycle analysis of indicated cell lines treated with KPT-185 at respective IC50 doses or control DMSO for 36 hours. Data shown as mean percentage in G1 phase. Supplementary Figure 4. Combinatorial effects of KPT-185 and cisplatin in OvCa cells. Supplementary Figure 5. Knockdown of p53 by p53 siRNA blocked the KPT-mediated apoptosis in CP70 cells. Supplementary Figure 6. P53 network following KPT-185 treatment in CP70 cells. Supplementary Figure7. Representative images and mutation status of original human tumor pathology specimens and paired PDX tumor sections.
Supplementary Figure 4 from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Authors: Kraft Ira L. , Akshintala Srivandana , Zhu Yuelin , Lei Haiyan , Derse-Anthony Claudia , Dombi Eva , Steinberg Seth M. , Lodish Maya , Waguespack Steven G. , Kapustina Oxana , Fox Elizabeth , Balis Frank M. , Merino Maria J. , Meltzer Paul S. , Glod John W. , Shern Jack F. , Widemann Brigitte C.
Published: April 2023

Weight-for-age and height-for-age growth curves. Male patient weights (A), heights (B) and female patient weights (C), and heights (D) were monitored during the follow up period. Patient weight-for-age and height-for-age values were compared to U.S. Center for Disease Control reference growth curves.
Figures S1 to S8 from Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma
Authors: Nandhu Mohan S. , Behera Prajna , Bhaskaran Vivek , Longo Sharon L. , Barrera-Arenas Lina M. , Sengupta Sadhak , Rodriguez-Gil Diego J. , Chiocca E. Antonio , Viapiano Mariano S.
Published: April 2023

Figure S1: Generation of mAb428.2 antibody; Figure S2: Affinity of mAb428.2 for fibulin-3; Figure S3: mAb428.2 binds to cell-surface and interstitial fibulin-3; Figure S4: mAb428.2 does not cause acute toxicity; Figure S5: Locally-delivered mAb428.2 targets fibulin-3 signaling and tumor growth; Figure S6: IV-delivered mAb428.2 inhibits tumor growth; Figure S7: Effects of mAb428.2 against intracranial tumors; Figure S8: Biodistribution of mAb428.2 in naïve and tumor-bearing mice.
Supplementary Figure 1b from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Authors: Kraft Ira L. , Akshintala Srivandana , Zhu Yuelin , Lei Haiyan , Derse-Anthony Claudia , Dombi Eva , Steinberg Seth M. , Lodish Maya , Waguespack Steven G. , Kapustina Oxana , Fox Elizabeth , Balis Frank M. , Merino Maria J. , Meltzer Paul S. , Glod John W. , Shern Jack F. , Widemann Brigitte C.
Published: April 2023

Patients #9, #12, #14, and #17 experienced progressive disease while on vandetanib therapy. Calcitonin and CEA are shown as percent change from baseline at the start of vandetanib therapy (left y-axis). Tumor size is the sum of longest diameter of lesions per RECISTv1.0 (right y-axis).
SupplementaryFigure S5 from Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells
Authors: Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Mesiano Giulia , Rotolo Ramona , Sassi Francesco , Sanlorenzo Martina , Zaccagna Alessandro , Pisacane Alberto , Senetta Rebecca , Cangemi Michela , Cattaneo Giulia , Martin Valentina , Coha Valentina , Gallo Susanna , Pignochino Ymera , Sapino Anna , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Supplementary Figure S5:Tumor infiltration by CIK cells
Table S1 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Authors: Neven Patrick , Jongen Lynn , Lintermans Anneleen , Van Asten Kathleen , Blomme Chantal , Lambrechts Diether , Poppe An , Wildiers Hans , Dieudonné Anne-Sophie , Brouckaert Olivier , Decloedt Jan , Berteloot Patrick , Verhoeven Didier , Joerger Markus , Vuylsteke Peter , Wynendaele Wim , Casteels Minne , Van Huffel Sabine , Lybaert Willem , Van Ginderachter Johan , Paridaens Robert , Vergote Ignace , Dezentjé Vincent Olaf , Van Calster Ben , Guchelaar Henk-Jan
Published: April 2023

List of participating centres and number of patients included.
Supplementary Tables S1-S5 from A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy
Authors: Luraghi Paolo , Bigatto Viola , Cipriano Elia , Reato Gigliola , Orzan Francesca , Sassi Francesco , De Bacco Francesca , Isella Claudio , Bellomo Sara E. , Medico Enzo , Comoglio Paolo M. , Bertotti Andrea , Trusolino Livio , Boccaccio Carla
Published: April 2023

Supplementary Table-S1: Somatic mutations in xenospheres Supplementary Table-S2: Pearson's correlation values between xenospheres' and xenopatients' gene expression profiles. Supplementary Table-S3: genes affected by copy number variations, as detected by WES in xenopsheres. Supplementary Table-S4: genes affected by somatic mutations, as detected by WES in xenopsheres. Supplementary Table-S5: total number of shared and private somatic mutations and copy number variations in matched xenospheres and xenopatients.
Supplemental Table S5 from High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Authors: Wang Sarah , Hwang Elizabeth E. , Guha Rajarshi , O'Neill Allison F. , Melong Nicole , Veinotte Chansey J. , Conway Saur Amy , Wuerthele Kellsey , Shen Min , McKnight Crystal , Alexe Gabriela , Lemieux Madeleine E. , Wang Amy , Hughes Emma , Xu Xin , Boxer Matthew B. , Hall Matthew D. , Kung Andrew , Berman Jason N. , Davis Mindy I. , Stegmaier Kimberly , Crompton Brian D.
Published: April 2023

Supplemental Table S5. Target sequences for shRNAs targeting AURKB and EWS/FLI expression
Supplementary Figure 3 from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Authors: Wang Dongsheng , Qian Guoqing , Zhang Hongzheng , Magliocca Kelly R. , Nannapaneni Sreenivas , Amin A.R.M. Ruhul , Rossi Michael , Patel Mihir , El-Deiry Mark , Wadsworth J. Trad , Chen Zhengjia , Khuri Fadlo R. , Shin Dong M. , Saba Nabil F. , Chen Zhuo G.
Published: April 2023

PDX tumor growth of patient 2,4,5 under the treatment of indicated drug
Supplementary Table 2 from Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
Authors: Qu Fangfang , Xie Wanling , Nakabayashi Mari , Zhang Haitao , Jeong Seong Ho , Wang Xiaodong , Komura Kazumasa , Sweeney Christopher J. , Sartor Oliver , Lee Gwo-Shu Mary , Kantoff Philip W.
Published: April 2023

Time to treatment failure (TTF) and overall survival (OS) in a subgroup of patients with blood draw within 6 months prior to therapy initiation
Figure S5 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental Figure 5. (A) Gating strategy of OCI-AML3 expressing CTRL or PKCÎµ shRNAs and stained with MitoSOX and Annexin V to evaluate mitochondrial superoxide production in viable leukemic cells (Annexin V-negative). (B) THP-1 transduced with CTRL shRNA or PKCÎµ shRNA were stained after 4 days post-transduction with MitoSOX and Annexin V (to exclude dead cells). The left panel is an illustrative histogram plot of a single experiment and the right panel show the MitoSOX MFI of live cells (Annexin V-) expressed as mean {plus minus} SD of three independent experiments. (C) Cells from patient-derived AML sample TUHS-AML-013 transduced with lentiviruses co-expressing GFP and CTRL, PKCÎµ shRNA_1 or SOD2 shRNA_1 shRNA and then analyzed at day 6 post-transduction with MitoSOX levels by flow cytometry. The bar graph shows the MFI of MitoSOX expressed as the mean {plus minus} SD of three technical replicates. (*p{less than or equal to}0.05; ***p{less than or equal to}0.001).
Figure S1 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental figure 1. THP-1, NOMO1, OCI-AML3 and U937 cell lines were transduced with CTRL shRNA or PKCÎµ shRNA_1, or PKCÎµ shRNA_2 and analyzed for (A) PKCÎµ expression by Western Blot analysis 4 days after transduction or (B) cell growth every 2 days by MTS analysis (Day 4, CTRL shRNA vs. PKCÎµ shRNA_1 or _2. ***p{less than or equal to}0.001;****p<0.0001). (C) Five days after transduction, cells were stained with Annexin V and analyzed by flow cytometry. Data are represented as the mean {plus minus} SD of three technical replicates. (***p{less than or equal to}0.001;****p<0.0001). (D) Seven day after transduction, THP-1 and OCI-AML3 were analyzed by flow cytometry for CD11b expression (***p{less than or equal to}0.001;****p<0.0001). (E) Wright - Giemsa staining of THP-1 infected with CTRL shRNA or PKCÎµ shRNA_1 and analyzed 7 days after infection (100X magnification - bar = 100ï�­m)
Figure S3 from Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus
Authors: Gavvovidis Ioannis , Leisegang Matthias , Willimsky Gerald , Miller Natalie , Nghiem Paul , Blankenstein Thomas
Published: April 2023

Transduction of MKL1 and PeTa cells with cDNA encoding HLA-A2
Figure S2 from Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus
Authors: Gavvovidis Ioannis , Leisegang Matthias , Willimsky Gerald , Miller Natalie , Nghiem Paul , Blankenstein Thomas
Published: April 2023

MAGE-A1 expression in MS-1 cells
Supplement Figure 2 from Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury
Authors: Yarana Chontida , Carroll Dustin , Chen Jing , Chaiswing Luksana , Zhao Yanming , Noel Teresa , Alstott Michael , Bae Younsoo , Dressler Emily V. , Moscow Jeffrey A. , Butterfield D. Allan , Zhu Haining , St. Clair Daret K.
Published: April 2023

Western blots of EV markers (CD63 and Alix) and endoplasmic reticulum marker (Calnexin) in SAL_EVs and DOX_EVs. The cell lysate was used as a positive control.
Supplementary movie 1 from Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculature and Metastasis
Authors: Tzeng Hong-Tai , Tsai Chung-Han , Yen Yi-Ting , Cheng Hung-Chi , Chen Yi-Chieh , Pu Shih-Wen , Wang Yu-Shiuan , Shan Yan-Shen , Tseng Yau-Lin , Su Wu-Chou , Lai Wu-Wei , Wu Li-Wha , Wang Yi-Ching
Published: April 2023

Time-lapse movie of TIRF images of EV-CE81T cells expressing GFP-tagged TSP1.
Supplementary Figure S6 from MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma
Authors: Ennen Marie , Keime Céline , Gambi Giovanni , Kieny Alice , Coassolo Sebastien , Thibault-Carpentier Christelle , Margerin-Schaller Fanny , Davidson Guillaume , Vagne Constance , Lipsker Dan , Davidson Irwin
Published: April 2023

SOX9 and SOX10 expression in sweat glands
Supplementary Figure S4 from MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma
Authors: Ennen Marie , Keime Céline , Gambi Giovanni , Kieny Alice , Coassolo Sebastien , Thibault-Carpentier Christelle , Margerin-Schaller Fanny , Davidson Guillaume , Vagne Constance , Lipsker Dan , Davidson Irwin
Published: April 2023

RNAscope on cultured MITF-high and MITF low cells
Supplementary Figure S3 from MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma
Authors: Ennen Marie , Keime Céline , Gambi Giovanni , Kieny Alice , Coassolo Sebastien , Thibault-Carpentier Christelle , Margerin-Schaller Fanny , Davidson Guillaume , Vagne Constance , Lipsker Dan , Davidson Irwin
Published: April 2023

Heatmaps of gene expression in tumours 3-5
Figure S3 from Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis
Authors: Liu Liang , Yang Lin , Yan Wei , Zhai Jing , Pizzo Donald P. , Chu Peiguo , Chin Andrew R. , Shen Meng , Dong Chuan , Ruan Xianhui , Ren Xiubao , Somlo George , Wang Shizhen Emily
Published: April 2023

Figure S3 shows that CCR2 is required for MCP-induced stemness
Legends to supplemental figures from Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Authors: Niu Xiaojia , Zhao Jianyun , Ma Jun , Xie Chengzhi , Edwards Holly , Wang Guan , Caldwell J. Timothy , Xiang Shengyan , Zhang Xiaohong , Chu Roland , Wang Zhihong J. , Lin Hai , Taub Jeffrey W. , Ge Yubin
Published: April 2023

Legends to supplemental figures
Supplementary Information and Figures from Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Authors: West Diana C. , Kocherginsky Masha , Tonsing-Carter Eva Y. , Dolcen D. Nesli , Hosfield David J. , Lastra Ricardo R. , Sinnwell Jason P. , Thompson Kevin J. , Bowie Kathleen R. , Harkless Ryan V. , Skor Maxwell N. , Pierce Charles F. , Styke Sarah C. , Kim Caroline R. , de Wet Larischa , Greene Geoffrey L. , Boughey Judy C. , Goetz Matthew P. , Kalari Krishna R. , Wang Liewei , Fleming Gini F. , Györffy Balázs , Conzen Suzanne D.
Published: April 2023

Supplementary Figures, Materials and Methods, and Descriptions of Supplementary files Supplementary Figure 1. Ligand displacement of GC from GR LBD. Supplementary Figure 2. C297 monotherapy is not cytotoxic in vitro or in vivo. Supplementary Figure 3. Mif and C297 antagonize Dex-regulated gene expression in MDA-MB-231 cells. Supplementary Figure 4. Dex-induced genome-wide GR peak locations (ChIP-seq) are lost by the addition of Mif or C297. Supplementary Figure 5. GR antagonists inhibit Dex-induction of canonical GR target genes, and transient knockdown of two additional target genes (MCL1 and NNMT) restores paclitaxel cytotoxicity in the presence of Dex. Supplementary Figure 6. Median and quartile association of NR3C1 expression with RFS in the Validation Cohort. Supplementary Figure 7. The GRsig is not predictive of RFS in ER+ BC patients. Supplementary Figure 8. GRsig expression in PDXs derived from TNBCs from the Mayo Clinic BEAUTY trial.
Supplementary File 3 from Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Authors: West Diana C. , Kocherginsky Masha , Tonsing-Carter Eva Y. , Dolcen D. Nesli , Hosfield David J. , Lastra Ricardo R. , Sinnwell Jason P. , Thompson Kevin J. , Bowie Kathleen R. , Harkless Ryan V. , Skor Maxwell N. , Pierce Charles F. , Styke Sarah C. , Kim Caroline R. , de Wet Larischa , Greene Geoffrey L. , Boughey Judy C. , Goetz Matthew P. , Kalari Krishna R. , Wang Liewei , Fleming Gini F. , Györffy Balázs , Conzen Suzanne D.
Published: April 2023

Graphical images of GR ChIP-seq peaks in regions flanking the TSSs of the n=31 GR putative direct target genes contained in the GRsig
Supplementary figure 3 from CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma
Authors: Fang Hsin-Yu , Münch Natasha Stephens , Schottelius Margret , Ingermann Jonas , Liu Haibo , Schauer Michael , Stangl Stefan , Multhoff Gabriele , Steiger Katja , Gerngroß Carlos , Jesinghaus Moritz , Weichert Wilko , Kühl Anja A. , Sepulveda Antonia R. , Wester Hans-Jürgen , Wang Timothy C. , Quante Michael
Published: April 2023

CXCR4 immunohistochemistry of a patient with EAC that has been imaged by [68Ga]CXCR4-PET/CT showing moderate infiltration with immune cells (open arrow) expressing CXCR4. Only very few epithelial tumor cells were detectable within this biopsy and they did not express CXCR4 (solid arrow)
Supplementary Table 7-10 from Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2
Authors: Chen Qun , Cai Jinquan , Wang Qixue , Wang Yunfei , Liu Mingyang , Yang Jingxuan , Zhou Junhu , Kang Chunsheng , Li Min , Jiang Chuanlu
Published: April 2023

Supplementary Table 7. Sequences of sgRNA and siRNA Supplementary Table 8. HOTAIR 5'mut and NEAT1 probe sequence Supplementary Table 9. PCR primer sequences Supplementary Table 10. Sequences of biotin probes
Supplementary figure 1 from CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma
Authors: Fang Hsin-Yu , Münch Natasha Stephens , Schottelius Margret , Ingermann Jonas , Liu Haibo , Schauer Michael , Stangl Stefan , Multhoff Gabriele , Steiger Katja , Gerngroß Carlos , Jesinghaus Moritz , Weichert Wilko , Kühl Anja A. , Sepulveda Antonia R. , Wester Hans-Jürgen , Wang Timothy C. , Quante Michael
Published: April 2023

(a) Gating example of flow cytometric analysis for CXCR4+CD45+CD11b+ myeloid cells, neutrophils (CD45+CD11b+Ly6G+F480-.), and macrophages (CD45+CD11b+Ly6G-F480+). (b-d) Flow cytometric analysis of ILCs (CD45+Cd3-Cd90.2+), NK cells (CD45+CD3-NK1.1+) and B cells (CD45+CD3-b220+) in esophagus of different time point mice (n=4-7). (e) Flow cytometric analysis shows an increase trend of CXCR4+CD45+CD11b+ myeloid cell populations in spleen (n=3, age=12 months).
Supplementary Table 1-4 from Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2
Authors: Chen Qun , Cai Jinquan , Wang Qixue , Wang Yunfei , Liu Mingyang , Yang Jingxuan , Zhou Junhu , Kang Chunsheng , Li Min , Jiang Chuanlu
Published: April 2023

Supplementary Table 1. The characteristics of CGGA database. Supplementary Table 2. The characteristics of Rembrandt database. Supplementary Table 3. The characteristics of TCGA database. Supplementary Table 4. The characteristics of GSE16011 database.
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Table S1 from Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
Authors: Oo Zay Yar , Stevenson Alexander J. , Proctor Martina , Daignault Sheena M. , Walpole Sebastian , Lanagan Catherine , Chen James , Škalamera Dubravka , Spoerri Loredana , Ainger Stephen A. , Sturm Richard A. , Haass Nikolas K. , Gabrielli Brian
Published: April 2023

Supplementary Figures and Table
Supplementary tables from Flt-3L Expansion of Recipient CD8α+ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD
Authors: Markey Kate A. , Kuns Rachel D. , Browne Daniel J. , Gartlan Kate H. , Robb Renee J. , Martins J. Paulo , Henden Andrea S. , Minnie Simone A. , Cheong Melody , Koyama Motoko , Smyth Mark J. , Steptoe Raymond J. , Belz Gabrielle T. , Brocker Thomas , Degli-Esposti Mariapia A. , Lane Steven W. , Hill Geoffrey R.
Published: April 2023

Supplementary table 1: Supplementary Table 1: Gene expression measured in QIAGEN Apoptosis Array; Supplementary Table 2: Antibodies
Figure S10 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary Figure 10: Systemic treatment of LN-308 glioma-bearing mice with ISTH1047 or ISTH0047 does not confer clinically relevant liver toxicity.
Supplementary tables from The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma
Authors: Wang Zheng , Hao Yajing , Zhang Chuanbao , Wang Zhiliang , Liu Xing , Li Guanzhang , Sun Lihua , Liang Jingshan , Luo Jianjun , Zhou Dabiao , Chen Runsheng , Jiang Tao
Published: April 2023

Supplementary tables Viruses Infection Status in Whole Grade Glioma
Figure S5 from The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma
Authors: Wang Zheng , Hao Yajing , Zhang Chuanbao , Wang Zhiliang , Liu Xing , Li Guanzhang , Sun Lihua , Liang Jingshan , Luo Jianjun , Zhou Dabiao , Chen Runsheng , Jiang Tao
Published: April 2023

Potentially prognostic viruses in glioblastoma
Figure S4 from The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma
Authors: Wang Zheng , Hao Yajing , Zhang Chuanbao , Wang Zhiliang , Liu Xing , Li Guanzhang , Sun Lihua , Liang Jingshan , Luo Jianjun , Zhou Dabiao , Chen Runsheng , Jiang Tao
Published: April 2023

PCR validation of SV40 and WMSV
Figure S1 from Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Authors: Saha Dipongkor , Wakimoto Hiroaki , Peters Cole W. , Antoszczyk Slawomir J. , Rabkin Samuel D. , Martuza Robert L.
Published: April 2023

Figure S1 shows cytotoxic effects of G47Î"-mIL12 in vitro in mouse cells and matrigel-based tube formation and CD31 expression in human GSCs
Suppl. Figure 6 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

(A) Semi-quantitative evaluation on immunohistochemically stained sections of the frequency of tumor cells expressing the potential T-cell target antigens CRKII, CFL1, NME2, and CNTN1 in astrocytoma (WHO{degree sign}II: n = 10, WHO{degree sign}III: n = 10) and (B) oligodendroglioma (WHO{degree sign}II: n = 10, WHO{degree sign}III: n = 10) tumor tissues.
Table S3 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Table S3
Supplementary Table S4 from A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Authors: Berger Martin D. , Stintzing Sebastian , Heinemann Volker , Cao Shu , Yang Dongyun , Sunakawa Yu , Matsusaka Satoshi , Ning Yan , Okazaki Satoshi , Miyamoto Yuji , Suenaga Mitsukuni , Schirripa Marta , Hanna Diana L. , Soni Shivani , Puccini Alberto , Zhang Wu , Cremolini Chiara , Falcone Alfredo , Loupakis Fotios , Lenz Heinz-Josef
Published: April 2023

Associations between GC rs4588 and clinical/molecular variables
Figure S5 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Supplemental figure S5: Gemcitabine and paclitaxel can upregulate IGF-1R and ErbB3 in pancreatic cancer cells.
Figure S4 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Supplemental Figure S4: Istiratumab restores activity of chemotherapy in the presence of IGF-1 and HRG.
Supplementary Data: Supplementary Tables S1-S6 from Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
Authors: Khoury Joseph D. , Wang Wei-Lien , Prieto Victor G. , Medeiros L. Jeffrey , Kalhor Neda , Hameed Meera , Broaddus Russell , Hamilton Stanley R.
Published: April 2023

Tables S1, S2, S3, S4, S5, S6
Supplementary Materials from Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
Authors: Hyman David M. , Rizvi Naiyer , Natale Ronald , Armstrong Deborah K. , Birrer Michael , Recht Lawrence , Dotan Efrat , Makker Vicky , Kaley Thomas , Kuruvilla Denison , Gribbin Matthew , McDevitt Jennifer , Lai Dominic W. , Dar Mohammed
Published: April 2023

SUPPLEMENTARY TABLES Supplementary Table 1. Treatment-emergent grade 3/4 adverse events in the safety population (n=116) Supplementary Table 2. MEDI3617 pharmacokinetic parameters Supplementary Table 3. Treatment outcome: objective response and progression-free survival, by cohort
Supplementary Figures from Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study
Authors: Zembutsu Hitoshi , Nakamura Seigo , Akashi-Tanaka Sadako , Kuwayama Takashi , Watanabe Chie , Takamaru Tomoko , Takei Hiroyuki , Ishikawa Takashi , Miyahara Kana , Matsumoto Hiroshi , Hasegawa Yoshie , Kutomi Goro , Shima Hiroaki , Satomi Fukino , Okazaki Minoru , Zaha Hisamitsu , Onomura Mai , Matsukata Ayami , Sagara Yasuaki , Baba Shinichi , Yamada Akimitsu , Shimada Kazuhiro , Shimizu Daisuke , Tsugawa Koichiro , Shimo Arata , Tan Ern Yu , Hartman Mikael , Chan Ching-Wan , Lee Soo Chin , Nakamura Yusuke
Published: April 2023

Supplementary Figure S1. ã€€ER status in breast cancer tissues was associated with Ki-67 response after tamoxifen therapy. (A) Ki-67 response was lower in the tissues in which the proportion of ER-positive cells was less than 2/3 than in the tissues in which the proportion of ER-positive cells was 2/3 or more. (B) In Allred score, a semi quantitative system, that takes into consideration the proportion of positive cells (scored on a scale of 0-5) and staining intensity (scored on a scale of 0-3), tissues with score of 7 or less showed lower Ki-67 response than those with score of 8. Supplementary Figure S2. Correlation between Ki-67 response and tumor response after tamoxifen therapy. No significant tumor response was observed by short-term pre-operative tamoxifen therapy. No correlation was also observed between the tumor response and Ki-67 response (Pearson correlation coefficient; R = -0.12). Tumor response was measured in bi-directional maximum dimension using ultrasound. Supplementary Figure S3. Relationship between Ki-67 response and pathological response after tamoxifen therapy. The breast cancer tissues with no pathological response (Grade 0) showed significantly lower Ki-67 response than those with Grade 1a or more pathological response. Supplementary Figure S4. Association between CYP2D6 genotypes and Ki-67 labeling index in pre-treatment tissue. CYP2D6 genotype was not associated with Ki-67 labeling index in pre-treatment tissue.
Supplementary Figure 4 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Authors: Slaney Clare Y. , von Scheidt Bianca , Davenport Alexander J. , Beavis Paul A. , Westwood Jennifer A. , Mardiana Sherly , Tscharke David C. , Ellis Sarah , Prince H. Miles , Trapani Joseph A. , Johnstone Ricky W. , Smyth Mark J. , Teng Michele W. , Ali Aesha , Yu Zhiya , Rosenberg Steven A. , Restifo Nicholas P. , Neeson Paul , Darcy Phillip K. , Kershaw Michael H.
Published: April 2023

ACTIV therapy induces cytokine secretion and apoptosis of tumor cells.
File S1 from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study
Authors: Moeung Sotheara , Chevreau Christine , Broutin Sophie , Guitton Jérôme , Lelièvre Bénédicte , Ciccolini Joseph , Massart Christophe , Fléchon Aude , Delva Rémy , Gravis Gwenaëlle , Lotz Jean-Pierre , Bay Jacques-Olivier , Gross-Goupil Marine , Paci Angelo , Marsili Sabrina , Malard Laurence , Chatelut Etienne , Thomas Fabienne
Published: April 2023

Description of the population pharmacokinetic model used to evaluate the inter-occasion (inter-day and inter-cycle) variability.
Supplemental Information from Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept
Authors: Almeida Afonso R. , Correia Daniel V. , Fernandes-Platzgummer Ana , da Silva Cláudia L. , da Silva Maria Gomes , Anjos Diogo Remechido , Silva-Santos Bruno
Published: April 2023

Supplemental Methods, Reagents and Materials for DOT-cell production and testing; detailed DOT-cell phenotyping and yields; and complementary in vivo analyses.
Supplemental Figure Legends from Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
Authors: Yang Qingshan , Chen Lisa S. , Ha Min Jin , Do Kim-Anh , Neelapu Sattva S. , Gandhi Varsha
Published: April 2023

All four supplemental figure legends are in this file.
Supplementary Materials and Methods from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Authors: Xu Chunxiao , Zhang Yanping , Rolfe P. Alexander , Hernández Vivian M. , Guzman Wilson , Kradjian Giorgio , Marelli Bo , Qin Guozhong , Qi Jin , Wang Hong , Yu Huakui , Tighe Robert , Lo Kin-Ming , English Jessie M. , Radvanyi Laszlo , Lan Yan
Published: April 2023

Supplementary Materials and Methods
Figure S7 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Authors: Xu Chunxiao , Zhang Yanping , Rolfe P. Alexander , Hernández Vivian M. , Guzman Wilson , Kradjian Giorgio , Marelli Bo , Qin Guozhong , Qi Jin , Wang Hong , Yu Huakui , Tighe Robert , Lo Kin-Ming , English Jessie M. , Radvanyi Laszlo , Lan Yan
Published: April 2023

Metacore pathway analysis of Nanostring gene expression data.
Supplementary Data - Cases from Merkel Cell Carcinomas Arising in Autoimmune Disease Affected Patients Treated with Biologic Drugs, Including Anti-TNF
Authors: Rotondo John Charles , Bononi Ilaria , Puozzo Andrea , Govoni Marcello , Foschi Valentina , Lanza Giovanni , Gafà Roberta , Gaboriaud Pauline , Touzé Françoise Antoine , Selvatici Rita , Martini Fernanda , Tognon Mauro
Published: April 2023

in this supplentary data file cases are reported
Supplementary Table S5 from A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases
Authors: Montfort Anne , Pearce Oliver , Maniati Eleni , Vincent Benjamin G. , Bixby Lisa , Böhm Steffen , Dowe Thomas , Wilkes Edmund H. , Chakravarty Probir , Thompson Richard , Topping Joanne , Cutillas Pedro R. , Lockley Michelle , Serody Jonathan S. , Capasso Melania , Balkwill Frances R.
Published: April 2023

Age, disease stage and treatment of patients from the cohort used for plasma IgG1,2,3 and 4 dosage
Supplementary Materials from Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
Authors: Wu Licun , Allo Ghassan , John Thomas , Li Ming , Tagawa Tetsuzo , Opitz Isabelle , Anraku Masaki , Yun Zhihong , Pintilie Melania , Pitcher Bethany , Liu Geoffrey , Feld Ron , Johnston Michael R. , de Perrot Marc , Tsao Ming-Sound
Published: April 2023

Table S1. Effects of clinical pathological covariates on survivals of patients whose tumor did or did no establish xenograft (XG). Table S2. Response of xenograft tumors to cisplatin or/and pemetrexed in mice Supplementary Figure S1. Response of representative xenograft models to the treatment with cisplatin. Supplementary Figure S2. Representative images of histology and biomarkers from selected matching patient and xenograft tumors.
Supplementary Revised Figure S2 from MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53
Authors: Lakshmanan Imayavaramban , Salfity Shereen , Seshacharyulu Parthasarathy , Rachagani Satyanarayana , Thomas Abigail , Das Srustidhar , Majhi Prabin D. , Nimmakayala Rama Krishna , Vengoji Raghupathy , Lele Subodh M. , Ponnusamy Moorthy P. , Batra Surinder K. , Ganti Apar Kishor
Published: April 2023

Pharmacological inhibition of phospho JAK1/2 in lung cancer cells. A, Upon JAK1/2 inhibition by ruxolitinib, we observed decreased phosphorylation of STAT3 (Y705) but no change in STAT3 expression. B, Similar effect was also observed in MUC16-Cter overexpressed lung cancer. β-actin was used as loading control.